Partner David Rosen was quoted in a Law360 article on January 15, 2014 titled “4 Lessons From FDA’s Social Media Guidance.” The article discusses the first installment of U.S. Food and Drug Administration guidance on the use of social media to promote pharmaceuticals. Rosen was quoted saying, “I think the companies are going to have to work on trying to police that.”
People
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.